Eli Lilly and Company (LLY)
| Market Cap | 1.26T +43.7% |
| Revenue (ttm) | 86.46B +45.5% |
| Net Income | 27.58B +49.8% |
| EPS | 30.81 +50.7% |
| Shares Out | 890.75M |
| PE Ratio | 45.83 |
| Forward PE | 30.10 |
| Dividend | $6.92 (0.49%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 4,033,897 |
| Open | 1,365.40 |
| Previous Close | 1,354.00 |
| Day's Range | 1,364.58 - 1,419.67 |
| 52-Week Range | 850.51 - 1,453.00 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 1,453.40 (+2.94%) |
| Earnings Date | Oct 29, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,453.4, which is an increase of 2.94% from the latest price.
News
Monday's Final Takeaways: LLY Foundayo Update & Lame Duck Congress Session Starts
There were some quiet market movers even as a lot of the oxygen was taken by Nvidia (NVDA) and its investigation into CEO Jensen Huang. Marley Kayden and Sam Vadas turn to their top takeaways from Mon...
Eli Lilly's Weight-Loss Pill Shows Sleep Apnea Benefits. Can It Gain on Novo?
Lilly plans to seek FDA approval for Foundayo to treat sleep apnea, potentially giving its weight-loss pill an edge over Novo Nordisk's oral Wegovy.
Eli Lilly’s (LLY) Obesity Pill Found to Help with Sleep Apnea
Obesity medications have many health benefits.
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
U.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.
Lilly's Foundayo pill cuts sleep apnea severity by up to 44% in late-stage trial, with an FDA filing planned by year-end
Eli Lilly's daily obesity pill Foundayo cut breathing interruptions during sleep by up to 44% in a year-long Phase 3 program. Lilly plans to seek U.S. approval for obstructive sleep apnea by the end o...
Eli Lilly Stock (LLY) Gains After Canada Recommends Public Reimbursement of Its Alzheimer’s Drug
The breakthrough medication is not cheap.
US FDA orders new eye risk warnings for Ozempic, Zepbound
The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and diabetes...
Lilly's weight-loss pill meets main goal in late-stage sleep apnea study
Eli Lilly said on Monday its oral weight-loss drug Foundayo significantly reduced breathing interruptions during sleep in obese adults with moderate-to-severe obstructive sleep apnea, meeting the...
Eli Lilly announces ‘positive’ results from Phase 3 study of Foundayo
Eli Lilly (LLY) and Company announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo in adults with moderate-to-severe obstructive sleep ap...
Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Eli Lilly said its new obesity pill, Foundayo, significantly reduced the severity of the most common sleep-related breathing disorder in a late-stage trial. The drugmaker plans to file by the end of ...
Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
In adults with moderate-to-severe OSA and obesity or overweight, Foundayo reduced breathing interruptions during sleep by up to an average of 44%, with up to 32% of participants achieving remission or...
Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?
GLP-1 medications and dietary supplements could play complementary roles in managing obesity and supporting longer-term health, Novonesis CEO Ester Baiget told CNBC on Monday. "We have scientific evi...
Eli Lilly price target raised to $1,700 from $1,610 at Jefferies
Jefferies analyst Akash Tewari raised the firm’s price target on Eli Lilly (LLY) to $1,700 from $1,610 and keeps a Buy rating on the shares. The firm thinks the Street…
Novartis drops heart drug after it failed to prevent heart attacks
Novartis is ending development of pelacarsen in heart disease. In a study of more than 8,300 patients the drug cut Lp(a) levels by 78% but did not reduce heart attacks or strokes.
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement
Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.
Healthcare Stocks Fall as Market Rout Spreads
Global healthcare stocks fell Friday, hit by a rout that reached Europe and Asia and spread across sectors after hammering AI trades and U.S. markets earlier in the week.
Hims & Hers and Eli Lilly announce agreement to expand acces to Zepbound
Eli Lilly and Company (LLY) and Hims & Hers Health (HIMS) announced an agreement to help expand access to Zepbound, or tirzepatide, and Foundayo, or orforglipron. Through the agreement, eligible…
Eli Lilly, Hims & Hers enter pact to expand access to Zepbound and Foundayo
Eli Lilly (LLY) and Hims & Hers (HIMS) announced an agreement to help expand access to Zepbound and Foundayo. Through the agreement, eligible patients who receive a prescription from a…
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (or...
LifeMD expands access to Eli Lilly self-pay GLP-1 medicines
LifeMD (LFMD) announced an arrangement with Eli Lilly (LLY) that enables LifeMD’s affiliated pharmacy to directly dispense and ship Lilly’s self-pay GLP-1 medicines, including Zepbound and Foundayo, t...
Eli Lilly price target raised to $1,557 from $1,497 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,557 from $1,497 and keeps a Buy rating on the shares. The firm is applying a higher multiple to…
Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
Pivotal results from the Phase 3 TRIUMPH-1 and TRIUMPH-4 trials showed retatrutide delivered substantial reductions in knee pain and weight in adults with knee osteoarthritis and obesity, with some ex...
GLP-1 drugs help control prediabetes better than current standard medicine
Today we feature a trio of interesting studies that will be presented in detail at the American Heart Association scientific sessions in Chicago this weekend.